Citi Reiterates Buy on Microsoft (MSFT), Calls It a Top Software Pick
"MSFT remains a top pick in software, and we believe this week's announcement is another indication of the company's strong pricing power, which we believed combined with accelerating cloud/AI share gains can drive outsized returns."
Analysts on Wall Street currently have a consensus 'Buy' rating on the stock. The average price target of $631 implies a 20.65% upside; however, the Street-high target of $700 implies an upside of 33.7%.
Microsoft Corporation (NASDAQ:MSFT) provides AI-powered cloud, productivity, and business solutions, focusing on efficiency, security, and AI advancements.
While we acknowledge the potential of MSFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced or metastatic breast cancer who have already received endocrine-based therapy. The FDA has set a Prescription Drug User Fee Act/PDUFA action date of June 5, 2026. The NDA is based on data from the Phase 3 VERITAC-2 clinical trial, which showed a statistically significant and clinically meaningful improvement in median progression-free survival for vepdegestrant compared to fulvestrant. The trial enrolled 624 patients at 213 sites across 25 countries, with 270 of these patients having the ESR1 mutation. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. The results from this trial were recently presented at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting and published in The New England Journal of Medicine. Vepdegestrant is an investigational oral drug that functions as a PROteolysis TArgeting Chimera/PROTAC estrogen receptor degrader. This marks the first time a PROTAC has demonstrated a clinical benefit in breast cancer patients. Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Marshalls' (LON:MSLH) Strong Earnings Are Of Good Quality
Explore Marshalls's Fair Values from the Community and select yours Investors were underwhelmed by the solid earnings posted by Marshalls plc (LON:MSLH) recently. We have done some analysis and have found some comforting factors beneath the profit numbers. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. The Impact Of Unusual Items On Profit For anyone who wants to understand Marshalls' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by UK£5.2m due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Marshalls doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On Marshalls' Profit Performance Unusual items (expenses) detracted from Marshalls' earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Marshalls' statutory profit actually understates its earnings potential! And the EPS is up 10% over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. You'd be interested to know, that we found 1 warning sign for Marshalls and you'll want to know about this. Today we've zoomed in on a single data point to better understand the nature of Marshalls' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
Secret White House spreadsheet ranks US companies based on loyalty to Trump
Donald Trump has drawn up a scorecard for corporate America, ranking companies based on their loyalty to his administration. The highly unusual list ranks 533 businesses and trade organisations based on their efforts to champion the US president's 'one big beautiful bill', according to reports. Companies that have fared well deployed a variety of tactics – often trumpeting the benefits of an individual policy, such as Uber's celebration of Mr Trump's 'no tax on tips' proposal. The scorecard, which Axios said will aid decision-making on corporate requests, comes as part of Mr Trump's 'America First' agenda and protectionist policies. The chart allegedly ranks enterprises' levels of support as either strong, moderate or low based on a series of factors. Actions that affect a company's rating are said to include social media posts, adverts, press releases, video testimonials, attendance at White House events and other engagements related to 'OB3' – the administration's nickname for the president's set-piece tax and spending legislation. According to Axios, businesses seen as 'good partners' on the White House list include DoorDash, United Airlines, Delta Airlines, Uber, AT&T, Cisco, Airlines for America and the Steel Manufacturers Association. AT&T recently announced 'plans to more quickly build fiber infrastructure thanks to pro-investment policies in the one big beautiful bill act passed by Congress'. Meanwhile Airlines for America – which represents major US airlines including United and Delta – lauded the bill's $12.5bn (£9.2bn) investment in air traffic control. The spreadsheet is said to be an evolving document, to which businesses' support for other presidential initiatives can be added. The ranking 'helps us see who really goes out and helps vs those who just come in and pay lip service,' an official told the news outlet. 'If groups/companies want to start advocating more now for the tax bill or additional administration priorities, we will take that into account in our grading,' the official added. It is not clear which businesses rank low on the list but those likely to have taken a hit may include clean energy companies, who heavily criticised the bill's rollback of green incentives. Mr Trump has also clashed with Wall Street in recent weeks. The president this week hit out at David Solomon, the Goldman Sachs chief executive, saying the bank had been wrong to predict that imposing US tariffs would hurt the US economy. Posting on Truth Social, Mr Trump said the investment banker should focus on being a DJ – one of his former hobbies – and 'not bother running a major financial institution'. The president has also butted heads with the leaders of JP Morgan Chase and Bank of America, claiming the banks had refused to accept more than $1bn in deposits. Mr Trump has signed an executive order requiring banks not to discriminate against clients on political grounds, in a move that could cause further headaches for the industry. The White House has made public a parallel list tracking the so-called Trump effect, referring to announcements of investments in US manufacturing, production and innovation during the president's second term. It comes as the president is increasingly seeking to exert control over corporate America through protectionist measures, offering tax relief to businesses that bring jobs back to the US and threatening to impose tariffs on those that do not. Business leaders have scrambled to pay homage to the president, offering the US government stakes in their companies and even bestowing personal gifts on the president in a bid to avoid sanctions. Last week, US chip manufacturer Nvidia agreed for the US government to take 15pc of the company's revenues generated in China as part of an agreement to restart exports to Beijing. The unprecedented pact came after Mr Trump barred sales of Nvidia's H20 technology in China earlier this year to boost his tit-for-tat trade war with Beijing, wiping billions of dollars from the $4tn company's value in the process. Tim Cook, the Apple chief executive, last week agreed to invest $100bn in American manufacturing after the president pledged to impose 100pc tariffs on foreign microchip imports. The tech giant's commitment to US manufacturing – as well as Mr Cook's gift of a glass plaque with a 24-carat gold base – earned the company a reprieve from Mr Trump. The president said: 'If you've made a commitment to build (in the US), or if you're in the process of building (in the US), as many are, there is no tariff.'
